Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL740949 | 0.89 | SMN1; SMN2 (0.41) | SIGMAR1OPRM1KCNH2SMN1; SMN2L3MBTL1 | |
| SCHEMBL3979406 | 0.85 | L3MBTL1 (0.37) | SIGMAR1OPRM1KCNH2SMN1; SMN2L3MBTL1 | |
| SCHEMBL2762013 | 0.80 | SIGMAR1 (0.39) | SIGMAR1OPRM1KCNH2SMN1; SMN2L3MBTL1 | |
| SCHEMBL2762344 | 0.72 | SIGMAR1 (0.43) | SIGMAR1OPRM1KCNH2SMN1; SMN2L3MBTL1 | |
| SCHEMBL2762030 | 0.71 | SIGMAR1 (0.42) | SIGMAR1OPRM1KCNH2SMN1; SMN2L3MBTL1 | |
| SCHEMBL741073 | 0.67 | L3MBTL1 (0.42) | SIGMAR1OPRM1KCNH2SMN1; SMN2L3MBTL1 | |
| SCHEMBL2761683 | 0.66 | SMN1; SMN2 (0.39) | SIGMAR1OPRM1KCNH2SMN1; SMN2L3MBTL1 | |
| SCHEMBL2761877 | 0.63 | ACHE (0.44) | SIGMAR1OPRM1KCNH2SMN1; SMN2L3MBTL1 | |
| SCHEMBL740952 | 0.62 | BDKRB2 (0.43) | SIGMAR1OPRM1KCNH2GRM2POLB | |
| SCHEMBL7168257 | 0.60 | POLB (0.37) | SIGMAR1OPRM1KCNH2SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882689-B1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8476429-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8378119-B2 | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120172605-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-8211910-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| EP-2463274-A1 | Tri-or tetra-substituted-3-aminopyrrolidine deritatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-7842818-B2 | Process for preparation of tetrasubstituted 5-azaspiro[2.4]- heptane derivatives and optically active intermediates thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20090270637-A1 | PROCESS FOR PREPARATION OF TETRASUBSTITUTED 5-AZASPIRO[2.4]- HEPTANE DERIVATIVES AND OPTICALLY ACTIVE INTERMEDIATES THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090054648-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1930321-A1 | PROCESS FOR PREPARATION OF TETRASUBSTITUTED 5-AZASPIRO[2.4]- HEPTANE DERIVATIVES AND OPTICALLY ACTIVE INTERMEDIATES THEREOF | Daiichi Sankyo Company, Limited (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1882685-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-01-30 | — | — | EP | disclosed |
| EP-1882689-A1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172605-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DHPS, COASY, NQO2 | SIGMAR1 3402/4885OPRM1 3694/4885KCNH2 1767/4885 |
| US-20090270637-A1 | PROCESS FOR PREPARATION OF TETRASUBSTITUTED 5-AZASPIRO[2.4]- HEPTANE DERIVATIVES AND OPTICALLY ACTIVE INTERMEDIATES THEREOF | DHPS, SQLE, NQO2 | SIGMAR1 3153/4885OPRM1 3784/4885KCNH2 2641/4885 |
| US-20090054648-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | ACSL3, ARL1, NQO2 | SIGMAR1 1394/4885OPRM1 2105/4885KCNH2 670/4885 |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | AAAS, NPEPPS, TEAD4 | SIGMAR1 872/4885OPRM1 765/4885KCNH2 2260/4885 |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | TLR5, TEAD4, NAALAD2 | SIGMAR1 1238/4885OPRM1 821/4885KCNH2 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.